HTG Molecular Diagnostics Balance Sheet Health
Financial Health criteria checks 5/6
HTG Molecular Diagnostics has a total shareholder equity of $1.2M and total debt of $9.1M, which brings its debt-to-equity ratio to 750.2%. Its total assets and total liabilities are $13.6M and $12.4M respectively.
Key information
750.2%
Debt to equity ratio
US$9.06m
Debt
Interest coverage ratio | n/a |
Cash | US$6.53m |
Equity | US$1.21m |
Total liabilities | US$12.40m |
Total assets | US$13.61m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 65H's short term assets ($10.8M) exceed its short term liabilities ($6.8M).
Long Term Liabilities: 65H's short term assets ($10.8M) exceed its long term liabilities ($5.6M).
Debt to Equity History and Analysis
Debt Level: 65H's net debt to equity ratio (209.8%) is considered high.
Reducing Debt: 65H had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 65H has sufficient cash runway for 4 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: 65H is forecast to have sufficient cash runway for 4 months based on free cash flow estimates, but has since raised additional capital.